An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy

被引：0

作者：

Sevindik, Omur Gokmen ^{[1
]}

Ozkurt, Zubeyde Nur ^{[2
]}

Boga, Can ^{[3
]}

Besisik, Sevgi Kalayoglu ^{[4
]}

Ipek, Yildiz ^{[5
]}

Geduk, Ayfer ^{[6
]}

Harmandali, Aybuke ^{[7
]}

Salihoglu, Ayse ^{[8
]}

Sahin, Handan Haydaroglu ^{[9
]}

Sonmez, Mehmet ^{[10
]}

Vural, Filiz ^{[11
]}

Akay, Olga Meltem ^{[12
]}

Yuksel, Meltem Kurt ^{[13
]}

Maral, Senem ^{[14
]}

Ekinci, Omer ^{[15
]}

Kirkizlar, Hakki Onur ^{[16
]}

Tekinalp, Atakan ^{[17
]}

Demir, Nazli ^{[18
]}

Merter, Mustafa ^{[15
]}

Saydam, Guray ^{[11
]}

Alacacioglu, Inci ^{[19
]}

Yegin, Zeynep Arzu ^{[2
]}

Kasar, Mutlu ^{[3
]}

Mastanzade, Metban ^{[20
]}

Ozsan, Guner Hayri ^{[19
]}

机构：

[1] Medipol Univ, Istanbul, Turkey

[2] Gazi Univ, Fac Med, Ankara, Turkey

[3] Baskent Univ Hosp, Ankara, Turkey

[4] Istanbul Univ, Div Hematol, Dept Internal Med, Fac Med, Istanbul, Turkey

[5] Dr Lutfi Kartal City Hosp, Istanbul, Turkey

[6] Kocaeli Univ, Fac Med, Izmit, Turkey

[7] Tepecik Educ & Res Hosp, Izmir, Turkey

[8] Istanbul Univ Cerrahpasa, Fac Med, Istanbul, Turkey

[9] Gaziantep Univ, Sahinbey Res & Practice Hosp, Gaziantep, Turkey

[10] Karadeniz Tech Univ, Fac Med, Trabzon, Turkey

[11] Ege Univ, Fac Med, Bornova, Turkey

[12] Koc Univ Hosp, Istanbul, Turkey

[13] Ankara Univ, Fac Med, Ankara, Turkey

[14] Diskapi Yildirim Beyazit Training & Res Hosp, Ankara, Turkey

[15] Firat Univ, Fac Med, Elazig, Turkey

[16] Trakya Univ, Fac Med, Edirne, Turkey

[17] Meram Univ, Fac Med, Konya, Turkey

[18] Istanbul Sisli Hamidiye Etfal Educ & Res Hosp, Istanbul, Turkey

[19] Dokuz Eylul Univ, Fac Med, Alsancak, Turkey

[20] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkey

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-125

引用

页码：S102 / S103

页数：2

共 50 条

[21] Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa
Patel, Amila M.
Ho, Viet Q.
Shain, Kenneth H.
Sullivan, Daniel
Alsina, Melissa
Ochoa, Leonel
Nishihori, Taiga
Djulbegovic, Benjamin
Dalton, William
Baz, Rachid
BLOOD, 2011, 118 (21) : 1703 - 1703
[22] New drug approval: Ciltacabtagene autoleucel - in patients with relapsed or refractory multiple myeloma who received 3 or more lines of therapy
Chacon, Aurelia
Bobin, Arthur
Leleu, Xavier
BULLETIN DU CANCER, 2022, 109 (10) : 993 - 995
[23] Bacteriology of dentoalveolar abscesses in patients who have received empirical antibiotic therapy
Kulekci, G
Yaylali, DI
Kocak, H
Kasapoglu, C
Gumru, OZ
CLINICAL INFECTIOUS DISEASES, 1996, 23 : S51 - S53
[24] The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
Tzogani, Kyriaki
Camarero Jimenez, Jorge
Garcia, Isabel
Sancho-Lopez, Arantxa
Martin, Marc
Moreau, Alexandre
Demolis, Pierre
Salmonson, Tomas
Bergh, Jonas
Laane, Edward
Ludwig, Heinz
Gisselbrecht, Christian
Pignatti, Francesco
ONCOLOGIST, 2017, 22 (11): : 1339 - 1346
[25] Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib
Weber, Donna M.
Jagannath, Sundar
Sobecks, Ronald
Schiller, Gary
Chiacchierini, Lisa
Reiser, David
Oerth, Carol
Garcia-Vargas, Jose
Rizvi, Syed
BLOOD, 2008, 112 (11) : 1272 - 1272
[26] An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy
Goffe, B
Papp, K
Gratton, D
Krueger, GG
Darif, M
Lee, S
Bozic, C
Sweetser, MT
Ticho, B
CLINICAL THERAPEUTICS, 2005, 27 (12) : 1912 - 1921
[27] The frequency of infectious esophagitis in patients who have received radiation therapy to the thorax.
Early, DS
Perez, RA
GASTROENTEROLOGY, 1998, 114 (04) : A111 - A111
[28] Risk of secondary malignancy in patients with testicular cancer who have received radiation therapy
Lewinshtein, D.
Porter, C. R.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[29] Safety of zoledronic acid in patients who have previously received bisphosphonate therapy.
Yanagihara, R
Vogel, CL
Wood, AJ
Schnell, FM
Henderson, C
Kaplan, BH
Purdy, MH
Orlowski, R
Decker, J
Lacerna, L
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 767S - 767S
[30] Carfilzomib in combination with lenalidomide and dexamethasone or carfilzomib in combination with dexamethasone alone in patients with multiple myeloma who have received at least one prior therapy: Interim results of the non-interventional CARO study
Knauf, W.
Ammon, A.
Uhlig, J.
Merling, M.
Hurtz, H-J
Vannier, C.
Schulz, H.
Marschner, N.
Riedt, T.
Potthoff, K.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 189 - 190

← 1 2 3 4 5 →